Clostridium Diagnostics Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022-2027

Report Code: HCR 0835 Report Format: PDF + Excel

Clostridium Diagnostics Market Overview

Clostridium Diagnostics Market size is estimated to reach $1.9 billion by 2027, growing at a CAGR of 7.3% during the forecast period 2022-2027. Clostridium is a gram-positive bacterium that can be found in a variety of forms. Disease-causing form of Clostridium bacteria which causes Clostridium difficile infection (CDI), a gastrointestinal ailment, frequently considered synonymous with antibiotic-associated diarrhea (AAD), is Clostridioides difficile. Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii cause gas gangrene, muscle necrosis, botulism, tetanus, pneumonia, endocarditis, arthritis and peritonitis. Frequent use of antibiotics leads to rapid multiplication of Clostridium difficile bacteria, owing to the absence of good microflora attributed to the effect of frequent consumption of antibiotics. However, antibiotics like benzylpenicillin, sulfonamides, tetracyclines, metronidazole, vancomycin and carbapenems are used to cure the infection and fructooligosaccharides are proven to reduce the adhesion of clostridium. Various imaging modalities, including radiography, CT (Computed Tomography) and endoscopy, are used to diagnose this infection. Typical symptoms of Clostridium difficile include diarrhea, dehydration, fever, nausea, loss of appetite and weight loss. For the identification of Clostridium bacteria, monoclonal antibodies, DNA probes, differential light scattering, immunoassays, artificial intelligence, microcomputers & automation, flow cytometry, liposomes, MRI, chromatography and gel microdroplets are all potential diagnostic technologies. As per the Centers For Disease Control And Prevention (CDC), Clostridium perfringens bacteria are one of the most typical causes of foodborne illness (food poisoning) and these bacteria bring about almost 1 million illnesses in the U.S. every year. Almost 100 Clostridium species have been recognized. However, only 25 to 30 typically bring about human or animal ailment.

The increasing predominance of clostridium-related diseases and the growing population of the elderly are set to drive the Clostridium Diagnostics Industry. The surging technological progress expanded healthcare infrastructure and altered lifestyle of people are set to propel the growth of the Clostridium Diagnostics Market during the forecast period 2022-2027. This represents the Clostridium Diagnostics Industry Outlook.

Clostridium Diagnostics Market Report Coverage

The “Clostridium Diagnostics Market Report - Forecast (2022-2027)" by Industry ARC, covers an in-depth analysis of the following segments in the Clostridium Diagnostics Market.

By Testing Technology: Immunoassays [Enzyme immunoassay (EIA), Enzyme-Linked Immunosorbent assay (ELISAs), Enzyme Multiplied Immunoassay Technique (EMIT)], Molecular Diagnostics (PCR-based technologies, Fluorescent in situ hybridization (FISH), Peptide Nucleic Acids (PNA), Biochips) and Others.
By Variants: Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani, Clostridium sordellii.
By End Use: Hospitals, Commercial Or Private Laboratories, Public Health Laboratories and Others.
By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America) and Rest Of The World (Middle East, Africa).

Key Takeaways

  • Geographically, North America Clostridium Diagnostics industry accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the advanced healthcare infrastructure in countries like U.S. and Canada in the North American region.
  • Clostridium Diagnostics Market growth is being driven by the surging initiatives taken by the government like awareness programs to educate individuals and acceptance of portable point of care (POCT) products. However, the limited awareness regarding the test is one of the major factors hampering the growth of the Clostridium Diagnostics Market.
  • Clostridium Diagnostics Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Clostridium Diagnostics Market report. 
Clostridium Diagnostics Market: Market Share (%) By Region, 2021

For More Details On this report - Request For Sample 

Clostridium Diagnostics Market Segment Analysis - by Testing Technology:

The Clostridium Diagnostics Market based on testing technology can be further segmented into Immunoassays, Molecular Diagnostics and Others. The Molecular Diagnostics Segment held the largest Clostridium Diagnostics market share in 2021. This growth is owing to the increased application of PCR technology in clinical diagnostics, rising demand for personalized and precision medicine and technological advances and applications in drug development. As per a research paper published in the National Library of Medicine in 2019, Real-time PCR for the diagnosis of toxic genes is the most effective diagnostic method for accurate and early diagnosis of Clostridium difficile infection. With the surging application of progressive molecular diagnostics and with the launch of commercially accessible tests, conventional diagnostic methods have been repeatedly substituted by the more novel rapid antigen detection and molecular-based techniques which are further propelling the growth of the Molecular Diagnostics segment.

Furthermore, the Immunoassays segment is estimated to grow with the fastest CAGR of 7.7% during the forecast period 2022-2027 owing to the rising prevalence of Clostridium-related diseases and the immunoassay technology offering an easy solution for diagnosis of Clostridium bacteria which is good to use in clinical laboratories and health centers.

Clostridium Diagnostics Market Segment Analysis - by End-Use:

The Clostridium Diagnostics Market based on end-use can be further segmented into Hospitals, Commercial Or Private Laboratories, Public Health Laboratories and Others. The Hospitals segment held the largest Clostridium Diagnostics market share in 2021. This growth is owing to the use of improved diagnostic technology over time in hospitals. The majority of hospitals have their own clinical laboratories or tie-up. In such clinical laboratories, the diagnostics of Clostridium is possible owing to the application of advanced techniques like immunoassay and molecular diagnostic technology in hospitals which is further propelling the growth of this segment. Furthermore, antibiotics like benzylpenicillin, sulfonamides, tetracyclines, metronidazole, vancomycin and carbapenems are readily available in the hospital supporting the segment growth.

Furthermore, the Commercial Or Private Laboratories segment is estimated to grow with the fastest CAGR of 8.9% during the forecast period 2022-2027 owing to the increasing number of private diagnostic laboratories across the globe and reliable techniques used for diagnostic specific lab tests using fecal specimens with the application of these technologies showing higher results for clostridium detection. 

Clostridium Diagnostics Market Segment Analysis - by Geography:

The Clostridium Diagnostics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Clostridium Diagnostics Market) held the largest Clostridium Diagnostics market share with 32% of the overall market in 2021. The growth of this region is owing to the well-established healthcare infrastructure, high expenditure on health and the continued prevalence of Clostridium in the North American region. According to the Centers For Disease Control And Prevention (CDC), nearly about 29000 patients died within 30 days after initial diagnosis of Clostridium difficile and more than 80% of deaths occurred in patients aged 65 years or older in America. More than 4.8 billion costs are borne by healthcare-associated infections every year in the U.S. As per the many research activities and studies conducted on Clostridioides difficile infection (CDI), most of all CDI are community associated with a mean incidence rate of 20 -30 per 100000 population. The increasing prevalence of Clostridioides difficile infection (CDI) coupled with the availability of antibiotics like benzylpenicillin, sulfonamides, tetracyclines, metronidazole, vancomycin and carbapenems is further fuelling the growth of the Clostridium Diagnostics Market size in the North American region.

Furthermore, the Europe region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like Europe being a developed region with the best healthcare and infrastructure facilities. However, the prevalence of clostridium is very high in the European region. As per European Center for Disease Prevention and Control, the annual burden of healthcare-associated with CDI was 123997 per year. Also, the number of deaths directly associated with CDI was 3700 per year as observed every year. The continuous outbreak of clostridium is further fuelling the progress of the Clostridium Diagnostics Market size in the European region.

Clostridium Diagnostics - Market Drivers

Increasing Population Coupled with Rising Awareness about Clostridium Infection is Propelling the Growth of the Clostridium Diagnostics Market

The world population is increasing day after day owing to low mortality rates and advanced healthcare facilities. In 2022, there is around 7.9 billion human population all around the world. As per the BMC Infectious Diseases website, amidst essential investigations recording both healthcare-associated (HA-CDI) and community-associated CDI (CA-CDI) incidence rates for each country of interest, where CDI stands for Clostridioides difficile infection, incidence rates per 10,000 patient days in the U.S. were 8.00 and 2.00 for HA-CDI and CA-CDI, respectively. India ranks second in population after China with 138 crores in 2020 as per world bank data. According to recent studies published in the Indian Journal of Pathology & Microbiology, the prevalence of CDI is 20% - to 30% in India with a 25% mortality rate in elderly people. This kind of high rate of predominance and increasing awareness among the population about clostridium diseases with the presence of major market players, clostridium diagnostic kits and advancements in technology is further propelling the growth of the Clostridium Diagnostics Market size during the forecast period 2022-2027.

Soaring Advanced Technology for Clostridium Testing is Fuelling the Growth of the Clostridium Diagnostics Market

Diagnosis of Clostridium is very difficult without the use of advanced technology, owing to it demonstrating atypical symptoms. Advanced level techniques like PCR (Polymerase Chain Reaction), ELISA (Enzyme-Linked Immunosorbent Assay) and enzymatic methods are used to detect the disease. In clinical laboratories and diagnostic centers, PCR is used owing to its high sensitivity of PCR. Clostridium identification is 96%, with 86% and 99% positive and negative predictive values, respectively with a 96% accuracy rate in diagnosing clostridium detection status. The creation of ultrasensitive toxin tests and the extension of biomarkers that may be more C. difficile specific are examples of advancements in diagnostics. Geneproof, Biomerieux and Altona diagnostics are some companies providing PCR test kits for clostridium detection. The soaring advanced technology for Clostridium testing is therefore fuelling the growth of the Clostridium Diagnostics industry during the forecast period 2022-2027.

Clostridium Diagnostics Market - Challenges

High Cost of Technology used for Clostridium Detection is Hampering the Growth of the Clostridium Diagnostics Market

The advanced technology used for the detection of Clostridium is much more expansive than the immunoassay technique and thus increases the cost of treatment used for detection. In underdeveloped and poor countries, it is very luxurious and out of pocket to take such life-saving treatment and most of the population is away from such kind of treatment owing to the high-cost burden and nominal income. According to the World Health Organisation half of the population around the world lacks essential health services and every year 100 million are pushed into extreme poverty owing to the out-of-pocket health burden. These issues are restraining the growth of the Clostridium Diagnostics industry.

Clostridium Diagnostics Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clostridium Diagnostics Market. The top 10 Clostridium Diagnostics Market companies are:

  1. Abbott Laboratories
  2. Olympus Corporation
  3. Beckman Coulter/Danaher
  4. Siemens Healthineers
  5. bioMerieux S.A.
  6. F. Hoffmann-La Roche
  7. Chrono-log Corporation
  8. Diazyme Laboratories
  9. FUJIREBIO DIAGNOSTICS
  10. Sysmex Corporation

Recent Developments:

  • In March 2022, Cerebriu and Siemens Healthineers, declared their partnership to combine Cerebriu's patented Smart Protocol™ for Brain MRI-workflow automation software with the MRI machines of Siemens Healthineers. The application is designed to be included in the Open Workflow interface, which will permit solutions to be seamlessly integrated directly into the MRI examination workflow. Smart Protocol™ for Brain is planned to act in-process detection and protocol automation during image acquisition, offering personalized diagnostic imaging and guaranteeing the right data for differential diagnosis.
  • In July 2020, Diazyme Laboratories declared a partnership with Maccura Biotechnology for introducing an FDA EUA-approved SARS-COV-2 RT-PCR diagnostics test. Diazyme Laboratories Inc., a Life Science Affiliate of General Atomics, is situated in Poway, California. Diazyme utilizes its proprietary enzyme and immunoassay technologies to establish diagnostic test reagents run on automated chemistry analyzers and chemiluminescence instruments in user-friendly formats.
  • In February 2020, Olympus Corporation declared acquisition of FH ORTHO – an international Orthopaedic Company headquartered in Heimsbrunn, France, succeeding the close of a definitive agreement the two firms endorsed in the summer of 2020. The gain underscores Olympus’ dedication to extending in the burgeoning field of orthopedic minimally invasive surgery (MIS) both organically and by way of mergers and acquisitions. By gaining FH ORTHO, Olympus banks on its portfolio of innovative and patient-focused solutions that are utilized in MIS procedures in ligament repair, foot & ankle and trauma surgery.

Related Reports

Mycoplasma Testing Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0429

Respiratory Syncytial Virus Diagnostic Testing Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: HCR 0826

Ampicillin Market Analysis - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast Analysis

Report Code: CMR 0246

For more Lifesciences and Healthcare Market reports, please click here

1. Clostridium Diagnostics Market - Overview
    1.1 Definitions and Scope
2. Clostridium Diagnostics Market - Executive Summary
3. Clostridium Diagnostics Market - Comparative Analysis
    3.1 Company Benchmarking - Key Companies
    3.2 Global Financial Analysis - Key Companies
    3.3 Market Share Analysis - Key Companies
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Clostridium Diagnostics Market - Start-up Companies Scenario (Premium)
    4.1 Key Start-up Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Clostridium Diagnostics Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Clostridium Diagnostics Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porter Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Clostridium Diagnostics Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Clostridium Diagnostics Market – By Testing Technologies
    8.1 Immunoassays
        8.1.1 Enzyme immunoassay (EIA)
        8.1.2 Enzyme-Linked Immunosorbent assay (ELISAs)
        8.1.3 Enzyme Multiplied Immunoassay Technique (EMIT)
    8.2 Molecular Diagnostics
        8.2.1 PCR-based technologies
        8.2.2 Fluorescent in situ hybridization (FISH)
        8.2.3 Peptide Nucleic Acids (PNA)
        8.2.4 Biochips
    8.3 Others
9. Clostridium Diagnostics Market – By Variants
    9.1 Clostridium Difficile
    9.2 Clostridium Perfringens
    9.3 Clostridium Botulinum
    9.4 Clostridium Tetani
    9.5 Clostridium Sordellii
10. Clostridium Diagnostics Market – By End-Use
    10.1 Hospitals
    10.2 Commercial or Private Laboratories
    10.3 Public Health Laboratories
    10.4 Others
11. Clostridium Diagnostics Market - By Geography
    11.1 North America
        11.1.1 the U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 the U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Chile
        11.4.4 Colombia
        11.4.5 Rest of South America
    11.5 Rest of the World
        11.5.1 the Middle East
        11.5.2 Africa
12. Clostridium Diagnostics Market - Entropy
13. Clostridium Diagnostics Market – Industry/Segment Competition Landscape (Premium)
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Clostridium Diagnostics Market – Key Company List by Country Premium (Premium)
15. Clostridium Diagnostics Market - Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
    * "Financials would be provided to private companies on best-efforts basis."